RT Journal Article
SR Electronic
T1 Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2101724
DO 10.1183/13993003.01724-2021
A1 Devos, Timothy
A1 Van Thillo, Quentin
A1 Compernolle, Veerle
A1 Najdovski, Tomé
A1 Romano, Marta
A1 Dauby, Nicolas
A1 Jadot, Laurent
A1 Leys, Mathias
A1 Maillart, Evelyne
A1 Loof, Sarah
A1 Seyler, Lucie
A1 Moonen, Martial
A1 Moutschen, Michel
A1 Van Regenmortel, Niels
A1 Ariën, Kevin K.
A1 Barbezange, Cyril
A1 Betrains, Albrecht
A1 Garigliany, Mutien
A1 Engelen, Matthias M
A1 Gyselinck, Iwein
A1 Maes, Piet
A1 Schauwvlieghe, Alexander
A1 Liesenborghs, Laurens
A1 Belmans, Ann
A1 Verhamme, Peter
A1 Meyfroidt, Geert
A1 
YR 2021
UL https://publications.ersnet.org//content/early/2021/07/29/13993003.01724-2021.abstract
AB Background Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness.Methods In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study.Results Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%).Conclusions Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality.Early transfusion of 4 units of high neutralising-antibody-titre convalescent plasma in hospitalised COVID-19 patients does not reduce mortality or the need for mechanical ventilation.